PharmaCyte Biotech, Inc. (PMCB)

NASDAQ: PMCB · Real-Time Price · USD

0.4913

+0.0106 (2.21%)

Sep 3, 2026, 4:00 PM EDT - Market closed

PharmaCyte Biotech Financials Overview

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Operating Income	-5.3	-5.3	-4.38	-6.52	-6.46	-4.39
Net Income	-23.21	-23.21	23.36	-17.24	-4.32	-4.24
Earnings Per Share	-2.77	-2.77	3.19	-1.80	-0.22	-0.27
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Cash & Investments	37.08	37.08	15.54	50.18	68.04	85.4
Total Debt	-	-	-	-	-	-
Net Cash (Debt)	37.08	37.08	15.54	50.18	68.04	85.4
Net Cash Growth	138.65%	138.65%	-69.03%	-26.25%	-20.33%	3869.72%
Net Cash Per Share	4.43	4.43	2.12	5.24	3.49	5.50

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Operating Cash Flow	-5.15	-5.15	-2.98	-2.15	-3.79	-4.12
Free Cash Flow	-5.15	-5.15	-2.98	-2.15	-3.79	-4.12
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 4, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
PE Ratio	-	-	0.36	-	-	-